drugset
Drugs / TQH3906
last change Sep 2026 re-read 9 days ago

TQH3906

Small molecule targets TYK2 via inhibition

Developed for
psoriasis · inflammatory bowel disease · psoriatic arthritis · systemic lupus erythematosus
Investigated by
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Trials 6

today NCT07724366 · Ph 3 NCT07406035 · Ph 2 NCT07509892 · Ph 2 NCT06754891 · Ph 1 NCT06542614 · Ph 2 NCT06230588 · Ph 1
2024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT06754891 Jan 2025 → Jul 2027 expected inflammatory bowel disease Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. Recruiting No outcome recorded
Phase 1 NCT06230588 Feb 2024 → Apr 2025 psoriasis Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. Completed No outcome recorded
Phase 23 trials
Phase 2 NCT07406035 Jul 2026 → Aug 2027 expected psoriatic arthritis Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. Recruiting No outcome recorded
Phase 2 NCT07509892 Jun 2026 → Nov 2027 expected systemic lupus erythematosus Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Recruiting No outcome recorded
Phase 2 NCT06542614 Aug 2024 → Nov 2025 psoriasis Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. Completed No outcome recorded
Phase 31 trial
Phase 3 NCT07724366 Sep 2026 → Sep 2027 expected psoriasis Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. Recruiting No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as TQH3906 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06754891 ↗
5

NCT07406035 ↗

NCT07724366 ↗

NCT06542614 ↗

NCT07509892 ↗

NCT06230588 ↗
Action Inhibit “TQH3906 is a kinase inhibitor.” NCT06230588 ↗
Modality Small molecule “TQH3906 is a small-molecule inhibitor of tyrosine kinase.” NCT07406035 ↗
Route Oral “TQH3906 capsule for oral administration as a single or multiple dose for 7days.” NCT06230588 ↗
Target TYK2 “Tyrosine Kinase 2 (TYK2) inhibitor” NCT07509892 ↗